Pfizer (PFE) EBITDA Margin (2009 - 2026)
Pfizer (PFE) reported EBITDA Margin of 286.83% for Q1 2026, up 2760.0% year-over-year from 10.03% in Q1 2025, and down 1313.18% quarter-over-quarter from 23.64% in Q4 2025.
Pfizer (PFE) EBITDA Margin (2009 - 2026) Analysis & Trends
Pfizer (PFE) has 18 years of EBITDA Margin data on file, last reported at 286.83% in Q1 2026.
- EBITDA Margin for Q1 2026 came in at 286.83%, up 2760.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 72.46% (down 4104.0% YoY), and the FY2025 annual result was 33.13%, up 47426.0% from the prior year.
- EBITDA Margin eased to 286.83% in Q1 2026 per PFE's latest filing, from 23.64% in the prior quarter.
- Over five years, EBITDA Margin peaked at 47.01% in Q3 2022 and troughed at 2483.26% in Q3 2024.
- A 5-year average of 341.58% and a median of 196.8% in 2023 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2024 and 2025: EBITDA Margin sank 164612 bps in 2024, then surged 214196 bps in 2025.
- A 5-year view of EBITDA Margin shows it stood at 45.55% in 2022, then tumbled by 938 bps to 381.77% in 2023, then tumbled by 550 bps to 2483.26% in 2024, then jumped by 101 bps to 23.64% in 2025, then plunged by 1313 bps to 286.83% in 2026.
- Business Quant data shows PFE's EBITDA Margin at 286.83% in Q1 2026, 23.64% in Q4 2025, and 341.3% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 30.06% |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 47.98% |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 26.44% |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 26.60% |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -47.46% |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 30.94% |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 37.16% |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | -286.83% |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 24.65% |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | -286.83% |
| Dec 31, 2025 | 23.64% |
| Sep 28, 2025 | -341.30% |
| Jun 29, 2025 | -322.39% |
| Mar 30, 2025 | -314.43% |
| Sep 29, 2024 | -2,483.26% |
| Jun 30, 2024 | 18.57% |
| Mar 31, 2024 | 36.98% |
| Dec 31, 2023 | -381.77% |
| Oct 1, 2023 | -837.14% |
| Jul 2, 2023 | -172.78% |
| Apr 2, 2023 | -196.80% |
| Oct 2, 2022 | 45.55% |
| Jul 3, 2022 | 47.01% |
| Apr 3, 2022 | 41.27% |
| Oct 3, 2021 | 32.79% |
| Jul 4, 2021 | 35.67% |
| Apr 4, 2021 | 38.38% |
| Sep 27, 2020 | 32.28% |
| Jun 28, 2020 | 30.04% |